- Home
- UHS vs VTRS Comparison
UHS vs VTRS Comparison
Compare UHS & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHS
- VTRS
- Stock Information
- Founded
- UHS 1978
- VTRS 1961
- Country
- UHS United States
- VTRS United States
- Employees
- UHS N/A
- VTRS N/A
- Industry
- UHS Hospital/Nursing Management
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- UHS Health Care
- VTRS Health Care
- Exchange
- UHS Nasdaq
- VTRS Nasdaq
- Market Cap
- UHS 11.8B
- VTRS 14.0B
- IPO Year
- UHS N/A
- VTRS N/A
- Fundamental
- Price
- UHS $184.80
- VTRS $11.30
- Analyst Decision
- UHS Buy
- VTRS Hold
- Analyst Count
- UHS 18
- VTRS 3
- Target Price
- UHS $222.59
- VTRS $13.67
- AVG Volume (30 Days)
- UHS 538.6K
- VTRS 10.6M
- Earning Date
- UHS 02-25-2025
- VTRS 02-26-2025
- Dividend Yield
- UHS 0.43%
- VTRS 4.25%
- EPS Growth
- UHS 57.82
- VTRS N/A
- EPS
- UHS 15.03
- VTRS N/A
- Revenue
- UHS $15,417,759,000.00
- VTRS $15,048,500,000.00
- Revenue This Year
- UHS $11.20
- VTRS N/A
- Revenue Next Year
- UHS $6.32
- VTRS N/A
- P/E Ratio
- UHS $12.29
- VTRS N/A
- Revenue Growth
- UHS 9.93
- VTRS N/A
- 52 Week Low
- UHS $150.11
- VTRS $9.93
- 52 Week High
- UHS $243.25
- VTRS $13.62
- Technical
- Relative Strength Index (RSI)
- UHS 47.78
- VTRS 28.18
- Support Level
- UHS $181.96
- VTRS $11.13
- Resistance Level
- UHS $187.21
- VTRS $12.02
- Average True Range (ATR)
- UHS 4.61
- VTRS 0.32
- MACD
- UHS 1.18
- VTRS -0.09
- Stochastic Oscillator
- UHS 63.54
- VTRS 10.97
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.